Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke
Recruiting now NCT04475510
Run by Josep Rodes-Cabau · for 18 to 60 · All sexes · accepts healthy volunteers
What this study is about
To determine the safety of antithrombotic treatment discontinuation 12 months following successful transcatheter PFO closure.
Who can join (things the study team will check)
✅ You may be able to join if…
- Successful transcatheter PFO closure with any approved device
- Patients ≤60 years diagnosed with a cryptogenic stroke/TIA who have undergone successful transcatheter PFO closure
🚫 You may not be able to join if…
- RoPE score <6
- Residual shunt ≥moderate following PFO closure
- Atrial fibrillation following PFO closure
- Presence of ≥2 cardiovascular risk factors (smoking, hypertension, dyslipidemia)
- Diabetes mellitus
- Thrombophilia (factor V Leiden, factor II mutation, anticardiolipin antibodies, lupus anticoagulant, anti-b2 glycoprotein-I antibodies, protein C deficiency, protein S deficiency)
- Recurrent cerebrovascular event (stroke, TIA) within the year following PFO closure
- Failure to provide signed informed consent
- Absolute contraindications for an MRI study
Where this trial is running
- IUCPQ, Québec, Quebec, Canada
Who to contact
Josep Rodes-Cabau, MD · 4186568711 · josep.rodes@criucpq.ulaval.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT04475510.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.